



JUBILANT
LIFE SCIENCES



Partner of Choice to
Life Sciences Companies

Innovate | Collaborate | Accelerate



Contents

Jubilant - Partner of Choice	2
Our Values	4
Our Offerings	5
Presence Across Value Chain	
Our Business: Pharmaceuticals & Life Sciences Products and Services	6
A Life Science Products	
I. Life Science Ingredients	
a. Active Pharma Ingredients (APIs)	9
b. Proprietary Products & Exclusive Synthesis	10-13
c. Nutrition	14
d. Life Science Chemicals	14
II. Generics	
a. Radio Pharmaceuticals	15
b. Allergenic Extracts	16
c. Dosage Forms	17
B Life Science Services	
I. Pharmaceutical Contract Manufacturing (CMO) - Sterile & Non Sterile Products	18
II. Drug Discovery & Development Solutions	19-22
III. Healthcare	23
Research and Development	24-25
Business Excellence	26-27
Corporate Sustainability	28-29
Jubilant Across the Globe	30-31
Awards and Recognitions	32



Jubilant - Partner of Choice

Over the last three decades, Jubilant Life Sciences has emerged as an integrated pharmaceutical and life sciences solution provider offering services to customers across the globe. The Company's strategic focus is to innovate, collaborate and accelerate the process of delivering products to the market for its customers. Today we are recognised as a 'Partner of Choice' by leading global Pharma and Life Sciences companies.

Jubilant is the largest Custom Research and Manufacturing Services (CRAMS) Company and is one of the leading Drug Discovery and Development Solutions (DDDS) Companies of India.

Jubilant Life Sciences Limited, an integrated pharmaceutical industry player, is the largest Custom Research and Manufacturing Services (CRAMS) Company and one of the leading Drug Discovery and Development Solutions Companies of India. Leveraging its focus on innovation and customer satisfaction the Company serves its customers across 65 countries around the world.

Our key competitive advantages of having a presence across the pharma value chain, strong culture of innovation, focus on providing cost effective, high quality products and services has enabled us to build value for our customers which has strengthened our relationships with all our customers. Today we are recognised as a 'Partner of Choice' by all leading pharma and biotech companies.

Life Sciences – an exciting opportunity

The Life Sciences sector offers an exciting opportunity for Jubilant as outsourcing increasingly becomes a strategic imperative for the global pharmaceutical and life sciences companies. The global CRAMS market is experiencing rapid growth, much higher than the growth of the global pharma market. Worldwide the companies are experiencing a multi-fold increase in their R&D spend but a much lower productivity, leading to drying up of their research pipeline. The increase in patent expiries and Government's pressures to bring down healthcare costs has further added to the challenges faced by these companies.

These companies are looking at collaborations and partnerships with reliable companies



Innovating for Delivering Value

that can offer 'high quality' –'low cost' – 'on time' products and services in compliance with global manufacturing standards.

Jubilant - A Partner of Choice to Life Sciences Companies

As a Partner of Choice Jubilant offers the following to its customers:

- Contract manufacturing services at low cost with exceptional quality and customer service
- High quality, low cost drug discovery and development solutions for expanding pipeline of innovative products
- Products from pre-clinical to clinical, intermediate to finished stage in shorter time frames with high quality and low cost.

Multi Location CMO Model:

The key differentiator for Jubilant as the global CRAMS player is its multi-location advantage that enables the Company to meet customer needs of the CMO and CRO businesses through:

- Presence in North America and India for manufacturing of multi-dose formulations (sterile, semi-solid, oral) to meet innovator pharma companies requirements

- Presence in North America for Radiopharmaceutical products provides proximity to key customers and markets
- Clinical research capabilities with presence in USA, Europe and India that enables project management on global basis

Global Presence

The Company, headquartered in India, has rapidly transformed into a multinational organisation with a strong international presence through its subsidiaries in USA, Canada, Belgium and China.

Over 64% of the Company's overall revenues come from the International markets. The Company has eleven geographically diversified manufacturing facilities in India, USA and Canada. Many facilities are cGMP and cGLP Compliant and have ISO 9001: 2000, ISO 14001 and OHSAS 18001 accreditations and also have regulatory approvals from relevant international regulatory authorities.

The Company enjoys a strong financial position with revenues for FY2010 at Rs. 37,813 million (US\$ 813 million) which has grown multi fold during the last decade.

Our Values

The Company's journey is led by its core values – Inspire Confidence, Always Stretch, Nurture Innovation and Excellent Quality which has enabled the Company to deliver on its promise of Caring, Sharing and Growing.



We will carefully select, train and develop our people to be creative, empower them to take decisions, so that they respond to all stakeholders with agility, confidence and teamwork.



We stretch ourselves to be cost effective and efficient in all aspects of our operations and focus on flawless delivery to create and provide the best value to our stakeholders



By sharing our knowledge and learning from each other and from markets we serve, we will continue to surprise our stakeholders with innovative solutions.



With utmost care for the environment and safety, we will always strive to excel in the quality of our processes, our products and our services.

OUR PROMISE

Caring, Sharing, Growing

We will, with utmost care for the environment and society, continue to enhance value for our customers by providing innovative products and economically efficient solutions; and for our stakeholders through growth, cost effectiveness and wise investment of resources

Our Offerings

The Company's strategic thrust on moving up the pharma value chain has resulted in its presence across the spectrum through its products and services. Jubilant is well positioned as a cost effective and high quality manufacturer, delivering innovative solutions to its customers.

Presence Across Value Chain





Our Business

The Company's Pharma & Life Sciences business for FY2010 stood at US\$ 723 Mn. 73% of this business comes from Life Science products while 27% was contributed by Life Science services.

Pharmaceuticals and Life Sciences Products and Services

The Company's core Pharma and Life Sciences business has grown significantly during the last ten years, reflecting the Company's dedicated focus on being an integrated Pharma and Life Sciences products and services provider to the global pharma and life sciences companies.

Jubilant's key to success is its sustainable integrated business model, developed over a decade that enables the Company to offer products and services across the complete pharma value chain. The Company has gained reputation as a 'Partner of Choice' with the leading global pharma and biotech companies through its presence in India, USA, Canada, Europe and China. It offers its customers the advantage to engage for early drug discovery to development, manufacturing of advance intermediates to APIs, contract manufacturing of sophisticated sterile injectables, manufacturing of generic dosage forms to niche pharma

products like radiopharma and allergenic extracts. Jubilant Life Sciences also offers affordable healthcare services in India.

Moving up the value chain in geographies Company's Pharma & Life Sciences revenue from regulated markets has been growing at a CAGR of 47% and today it contributes almost 73% of the PLSPS international revenues.

The Company's Pharmaceuticals and Life Sciences Products & Services (PLSPS) business comprises two major building blocks of Life Science Products and Life Science Services.



Life Science Products

Today the Company offers over 165 products including Pyridine, Picolines and Cyanopyridines, all developed in-house by its research and development team.

Life Science Products is the core segment of the PLSPS business constituting 73% of the pharma & life sciences business revenues. The Company is a global leader in Pyridine and has developed a range of pyridine derivatives using its technological expertise in this area.

Today the Company offers over 165 products based on Pyridine chemistry all developed in-house by its research and development team. Pyridine is an excellent industrial solvent with applications in Pharma & Life Sciences and Agro Chemicals.

The Company is a leading provider of Nutrition products and is the third largest producer of Vitamin B3, in the world.

Over the years the Company has built a sizable business in the Active Pharmaceutical

Ingredients (APIs) area and provides a range of products to leading global pharma companies. It has achieved global leadership in some of the key products like Lamotrigene, Carbamazepine, Oxcarbazepine, Citalopram and Risperidone.

The Company's generic dosage forms business in USA has also grown significantly, today many of its products rank amongst the top three in the market. Similarly in the area of radiopharma products the Company enjoys leadership position for I-131 product in the USA markets and in allergy area it is amongst the top three allergy therapy companies in the world.

The Company offers **Life Science Ingredients** and **Generics** in the Life Science Products business.

<p>Life Science Ingredients</p>	<p>API</p> <ul style="list-style-type: none"> • Provider of bulk drugs to generic pharma companies • Focus on therapeutic segments - CVS, CNS, Gastro-intestinal and anti-infectives <p>Proprietary Products & Exclusive synthesis</p> <ul style="list-style-type: none"> • Custom manufacture of advanced intermediates, innovator active ingredients & preparatory products to global pharma and agrochemical companies • Service offering include route design, process development & analytical method development <p>Nutrition</p> <ul style="list-style-type: none"> • Leading provider of nutritional ingredients for pharma, human and animal applications such as Niacin, Niacinamide and Choline Chloride <p>Life Science Chemicals</p> <ul style="list-style-type: none"> • Product supplies to Life science industry such as Acetic Anhydride and Ethyl Acetate 	<p>Globally No. 1 in carbamazepine, oxcarbazepine, Lamotrigines and No. 2 in Citalopram, Risperidone in generics</p> <p>Globally No. 1 in Pyridines & 11 advance intermediates</p> <p>Globally No. 3 in Vitamin B3 (Niacin & Niacinamide)</p>
<p>Generics</p>	<p>Radio Pharmaceuticals</p> <ul style="list-style-type: none"> • Development, manufacture and marketing of radiopharmaceutical products for diagnostic and therapeutic use <p>Allergenic Extracts</p> <ul style="list-style-type: none"> • Major therapeutic and diagnostic extracts for allergy derived from pollens, animals and stinging insects venoms <p>Dosage Form</p> <ul style="list-style-type: none"> • Provider of high quality finished dosage forms (tablets and capsules) 	<ul style="list-style-type: none"> • Leader in I-131 in USA with ~69% market share • Globally among top 3 in several Generics • Globally among top 3 leading allergy therapy companies

Life Science Services

Moving up the value chain Jubilant has built a strong capability in the area of Life Science Services that constitute Drug Discovery and Development Solutions (DDDS), CMO of Sterile and non-sterile products and healthcare services.

Jubilant is a pioneer and the largest provider of integrated DDDS out of India through its facilities in India, Europe and North America. The Company collaborates with major global pharma and biotech companies to accelerate their quest for developing affordable innovative solutions for the patients worldwide.

The Company, through its wholly owned subsidiaries HollisterStier and Draxis in North America enjoys a strong position in CMO business of Sterile and Non-sterile Injectables in the North American markets.

Extending its presence to the other end of the pharma spectrum the Company is extensively

engaged in setting up a hub and spoke model of thousand beds aimed at offering affordable, world class health care delivery services for the middle and lower middle class in West Bengal, India.

The Company has been growing steadily in its core pharma and life sciences business and has relationships with 18 of the top 20 global pharma companies and 7 of the top 10 agrochemical companies. Through its consistent product quality and on time delivery it has gained a reputation of a strong and reliable partner.

CMO - Sterile & Non Sterile Products	<ul style="list-style-type: none"> • CMO Services for Lyophilized Product, liquid fills, biologics, suspensions, liposomes, devices and WFI / diluent and clinical trial quantities • CMO services for ointment, cream and liquid • CMO for oral dosage forms 	Leading player in North America in CMO for Sterile injectables
Drug Discovery & Development Solutions	<ul style="list-style-type: none"> • Providing integrated Drug Discovery and Development Solutions to global pharma and biotech companies • Discovery Research: Target to IND, functional services, medicinal chemistry and scale up synthesis • Clinical Research: Integrated from Phase I to Phase IV in US, Europe and India • JV with Lilly for managing drug development from Pre-clinical to Phase II - proof of concept 	Leading player in India in Drug Discovery & Development Solutions
Healthcare	<ul style="list-style-type: none"> • A hub & spoke model to provide affordable high-quality health care services in West Bengal, India, plans to set up total of 1000 beds (currently 265 beds operational) 	

Global Leadership

- Globally No.1 in Carbamazepine, Oxcarbazepine, Lamotrigine APIs and No. 2 in Citalopram & Risperidone in generics APIs
- Globally No.1 in Pyridine & 11 advance intermediates
- Leader in I-131 radiopharma product in USA
- Leading player in North America in CMO for Sterile injectables
- Globally among top 3 Allergy therapy companies
- Globally No. 3 in Vitamin B3 (Niacin & Niacinamide)
- Globally among top 3 in several Generic dosage forms
- Leading player from India in Drug Discovery & Development Solutions

Active Pharmaceutical Ingredients

Jubilant Life Sciences is one of the largest Active Pharmaceutical Ingredients (APIs or Bulk Actives) manufacturers in the world. Over the years, the Company has developed its reputation as a manufacturer with high quality standards and with audits and approvals from US FDA, AFSSAPS (France) and PMDA (Japan).

Under API, Jubilant has a focused presence in therapeutic segments such as Central Nervous System (CNS), Cardiovascular System (CVS), Gastrointestinal and Anti-infectives. It is a major player in products like Carbamazepine, Oxcarbazepine, Lamotrigine, Donepezil, Olanzapine, Citalopram, Risperidone, Valsartan, Pantoprazole, Esomeprazole and Irbesartan.

The Company currently has over 20 APIs, available through commercial scale plants. It has filed 38 Drug Master Files (DMFs) in the US

and 20 Drug Master Files in Europe, 20 DMFs in Canada, 5 DMFs in Japan, 6 DMFs in Australia, 7 DMFs in New Zealand. Further, the Company has 25 products under active development. The focus of Research and Development continues to be on non-infringing processes to produce APIs for the global generics market.

The R&D centre also provides contract research services to the global pharmaceuticals and life sciences industry.



Generic APIs offer

Patent non-infringing processes

State-of-the-art pilot and commercial scale multipurpose plants at Nanjangud (near Mysore) approved by various regulatory authorities such as US FDA, AFSSAPS (France) and PMDA (Japan).

Strong regulatory, R&D & IPR support

Robust pipeline with good therapeutic width

Preemptive capacity planning

Speed to Market

Customer Orientation

At the Company's R&D centre at Noida, over 150 scientists dedicated to the development of APIs focus on developing non-infringing processes, novel polymorphs and continuous cost reduction facilitating the first-to-file advantages in ANDAs and dossiers in regulated markets.

Proprietary Products – Advance Intermediates

Jubilant enjoys no. 1 position globally in pyridine and its derivatives which are used as solvents, basic building blocks and advance intermediates with wide application in Pharmaceuticals, Agrochemicals, Life Sciences, Healthcare and other industries.

Jubilant provides a range of advance intermediates comprising Pyridine and its derivatives, through its world scale EHS & cGMP compliant manufacturing facilities.

The Company leverages its backward & forward integration to achieve global cost leadership in Pyridine & its derivatives market.

Products	Offerings
Pyridine	A versatile building block and excellent solvent in agrochemical, pharmaceutical, healthcare, marine paints, dyes, metal finishing, electronics and other industries.
Alpha Picoline	Used mainly to manufacture 2-Vinyl Pyridine and finds application in various agrochemicals and pharmaceuticals.
Beta Picoline	Used in agrochemicals, Vitamin B-3 and various pharmaceutical intermediates.
Gamma Picoline	Finds application in pharmaceuticals, polymers, dyes and textiles.
2-Cyanopyridine	Major application in agrochemicals, pharmaceuticals, metal plating and precious metal recovery.
3-Cyanopyridine	Used to manufacture Niacin and Niacinamide and various agrochemicals.
4-Cyanopyridine	Mainly used to manufacture Isoniazid. Also used in pharmaceutical and agrochemical intermediates.
Piperidine	The major application of Piperidine is for production of Dipiperidinyl dithium tetrasulfide, which is used as a rubber vulcanization accelerator. It is also used as an epoxy resin curing agent, in dye production in agrochemicals and pharmaceuticals.



Proprietary Products – Fine Chemicals

Jubilant's Fine Chemicals business offers about 165 products developed through in-house R&D and awaiting commercialisation. These are mainly Pyridine and Piperidine based intermediates which find application in about 250 APIs and 50 Agrochemicals.

Jubilant holds globally No.1 position in Amino Pyridines, Lutidines and Collidines and for most of the other products, it enjoys a leading position in the global market.

Over the last 10 years, the Fine Chemicals business has been granted 28 process patents in various countries including India, Japan and PCT Union.

Over sixty products have already been commercialised and are being supplied

to about 145 customers globally. These customers include Innovators, Generic Pharma, Agro Companies, Personal Care and other Fine & Speciality Chemical companies.

Fine Chemical Products are produced in India at seven multipurpose manufacturing plants at Gajraula, UP and two multipurpose plants at Ambarnath, Maharashtra.

Key Product Offerings

Over 60 Commercialised Fine Chemicals

Product Groups	No of Products
Lutidines	6
Collidines	2
Amino Pyridines	6
Amino/Hydroxy/ChloroMethyl Pyridines	7
Pyridine Quart Salts	3
Pyridine Carboxylic Acids and Derivatives	9
Pyridine Aldehydes	2
Chloro Pyridine and Derivatives	17
Piperidine Derivatives	6
Other Products	4

As the largest CRAMS Company in India, Jubilant has successfully translated the India advantages into value offerings for its customers.



Exclusive Synthesis – Intermediates & APIs

Jubilant has expertise in developing and manufacturing complex chemical processes. Using this expertise, Jubilant provides Process Development and Manufacturing Services to Life Sciences Industry for Intermediates and APIs.

The Exclusive Synthesis business leverages integrated R&D, technology and engineering capabilities that enables it to be the cost effective partner on a sustainable basis.

By capitalising on the scientific expertise and knowledge resident across the organisation, Jubilant has created a demonstrable value proposition with its custom research solution.

Business Offerings

Research & Developmental Services (Intermediates & APIs):

- Routes design, process development and process optimisation for early phase clinical projects in pre-clinical / phase I to III
- Cost effective process development and optimisation for in-market and launched products
- Analytical protocol development with complete dossier preparation on demand

These processes are developed with emphasis on being environment friendly, scalability, ease of operation and process robustness. Jubilant often makes use of statistical Design of Experiments (DOE) for developing these processes.


Custom Manufacturing (Intermediates & APIs):

The Company takes up manufacturing projects of developmental products in Clinical phase as well as of in-market products from a few Kilograms to several Metric ton quantities on a regular basis.

The business handles projects having:

- **Process received from the customer:** Through process familiarisation, contractual agreement, complete technology transfer, commercial manufacturing
- **Process to be developed:** Through route selection, sample preparation, sample approval, process optimisation, contractual agreement, pilot trial, commercial manufacturing





Project Management

Every project of the customer is handled with due care by a dedicated Project Manager to ensure:

- One Point of Contact for customer who coordinates internally with various functions
- Identifies risks and their mitigation plans to ensure timely implementation of Projects
- Communicates periodically with customers on project progression, documentation etc. on a mutually agreed reporting format and timelines. As and when required Project Manager brings cross-functional team on board to have interactions with the customers
- Jubilant has implemented Enterprise Project Management (EPM) in order to track the deliverables of various functions by top level management.
- Enterprise Project Management (EPM) Web Based Tool: It identifies, records, shares, tracks, resolves and communicates all issues pertaining to the project.
- Project Management Professional Certification: For correct application of Tools and Techniques, all Project Managers and key functional contributors in CRAMS projects have to obtain 35 Hrs Professional Development Units (PDU's) by taking a 5 day session on PMP certification program conducted by PMI (Project Management Institute) and clearing the examination.

Core Technology Platforms

- Aromatisation
- Vapour Phase Reaction (upto 450°C)
- Chichibabin Reaction
- Stereo Selective Hydrogenation
- High Pressure Hydrogenation (upto 58 kg pressure at 6KL reactor)
- Butyl Li Reaction (upto -80°C)
- Alkylation / Methylation
- Oxidation
- Quaternisation
- Grignard Reaction
- Phosphate Esters / POCl_3 handling
- Sodamide / Sodium methoxide Reaction
- Sandmeyer Reaction
- Fermentation etc.
- Halogenations (Including Photo chlorination)
- Ammoxidation
- Beckmann Rearrangement
- Mannich Reaction

Our classical technologies are also being used at various levels of manufacturing.

Nutrition

Jubilant is a significant player in the nutrition market, it manufactures and markets a wide range of nutritional ingredients and formulations for applications across pharma, food, animal feed and personal care.

The nutrition ingredients portfolio largely comprises Niacin and Niacinimide – key derivatives of Pyridine. The Company ranks among the top three manufacturers of Niacin and Niacinimide in the world.

The Company enjoys a strong position of trust and reliability with its customers across the globe, on account of quality of its products and services. Our manufacturing facilities are certified by international regulatory authorities and our products conform to major international pharmacopoeias.

Jubilant is present in the animal nutrition business through Choline Chloride and Niacin / Niacinamide products that are used as supplements for poultry, cattle, swine and in aquaculture. Other products include feed supplements like vitamins & trace mineral premixes, speciality products and toxin binders (Typically used in poultry for mycotoxin management).

Jubilant is expanding Nutrition business further and putting up 10,000 MT Niacinamide plant (along with 10,000 MT 3-Cyano Pyridine plant) in SEZ in Gujarat, India, to be operational within current financial year.

Products	Offerings
Niacin and Niacinamide	Used in pharmaceuticals, human nutrition, animal feed, cosmetics and other industries
Choline Chloride	Used in pharmaceuticals and as a feed supplement in poultry, dairy, swine and aqua industry.
Enzymes	Used as a feed supplement in poultry and dairy industry.
Premixes	Used as a feed supplement in poultry, dairy, swine and aqua industry.
Specialty & Other Ingredients	Used as a feed supplement in poultry, swine and dairy industry.

Life Science Chemicals

Jubilant manufactures a range of life science chemicals of Acetyl group and holds leadership position in most of them.

Jubilant focuses on customizing the products through superior quality and just in time delivery. Six sigma initiatives are adopted where the Company constantly benchmarks and improves the product line – up to enhance efficiency measures.

Acetyls

Jubilant offers a basket of acetyls products, these include; Acetaldehyde, Acetic Acid, Ethyl Acetate, Acetic Anhydride, MCAA (Monochloroacetic Acid), SMCA (Sodium Monochloro Acetate), VAM and n-Butyl Acetate. It has 2 fully integrated Acetyls production sites at Gajraula (UP) and Nira (Maharashtra). Acetyls find applications in diverse industries such as Pharmaceutical, Crop Protection, Food & Beverages, Textiles, Packaging, Adhesives, Aromatics etc.

Jubilant is ranked amongst top ten globally in:

- Acetaldehyde
- Acetic Anhydride
- Ethyl Acetate

Speciality Gases

Product offerings include Carbon di-oxide and Mixtures of Carbon di-oxide and Ethylene oxide which mainly find applications in Beverage, Healthcare and Engineering Industry.

Radiopharmaceuticals

DRAXIMAGE, the radiopharmaceutical division of Draxis, a subsidiary of Jubilant Life Sciences, develops, manufactures and markets innovative diagnostic imaging radiopharmaceutical solutions and therapeutic radiopharmaceutical products for the global market.

Product portfolio

- Hicon (I-131 solution)
- Iodine – 131 (diagnostic and therapeutic capsules)
- Chromium – 51
- Xenon – 133
- Phosphorous P – 32

Applications include cardiology, oncology, thyroid uptake and scan, lung scan, kidney imaging, brain imaging, bone scan etc.

Draxis is the major supplier of lyophilised radiopharmaceutical kits for use with Technetium-99m including DRAXIMAGE MAA, MDP, DTPA, Glucoheptonate and Sestamibi.

Draximage I-131 products are the market leader in the US with more than 70% market share. I-131 products are currently the major revenue driver for the Company.

The Company has a strong research setup and has created a robust pipeline of products.

- Sestamibi, a generic version of Cardiolite, approved by USFDA and Health Canada is used in cardiac stress testing to evaluate blood flow to the heart, was launched after Patent expiry in July 2009
- MolyFill, next generation Technetium generator, Technetium 99m is used to reconstitute lyophilised radiopharmaceutical kits at the hospital / radiopharmacy
- Rubidium Generator finds application in distinguishing abnormal myocardium in patients with suspected myocardial infarction. Rubidium 82 is produced from the decay of Strontium 82



Allergenic Extracts



HollisterStier Allergy is a full service provider to the allergy speciality with a product range of over 200 different allergens and standard mixes of allergy vaccines.

HollisterStier Allergy, located in Spokane, Washington, USA, is a subsidiary of Jubilant Life Sciences. It is a world leader in the manufacturing of allergenic extracts targeted primarily at treating environmental allergies and asthma. It is one of the leading North American immunotherapy companies with around 90 years of experience and brand loyalty.

Products like the Venom line, diagnostic set and allergenic extracts, AP extracts, QUINTIP & ComforTen diagnostic skin test devices makes Allergy business

stand out as a leader in the industry.

The Company is dedicated to being your partner in allergy management. The Company's allergy products are among the highest quality and reliability of allergenic extracts and allergy equipment available today. The product line is based on scientific consensus of leading botanists, practicing allergists and technical operations specialists. HollisterStier Allergy is committed to providing the quality you expect and the service you deserve.

ALLERGENIC EXTRACTS

Tree Pollen

Weed Pollen

Grass Pollen

Epidermals and Inhalants

AP™ Standardised Cat Extracts

Insects

Standardised Mite Extracts

Venoms

Foods

Molds

ALLERGY PRODUCTS AND SUPPLIES

ComforTen™ Multiple Skin Test Device & Histamine

Diagnostic Services

Diagnostic Controls

Vials

Diluents

Racks

Trays

Pulmonary Supplies

Syringes

Vial Supplies

Storage and Shipping Containers

Educational/Reference Materials

Dosage Forms

The Generic dosage form business of Jubilant is well placed to expand and serve the multiple markets across the globe. With complete backward integration into APIs and in-house bio-equivalence centre, the Company offers speed to market and cost competitiveness to its customers enabling them to remain competitive in the market place.

Jubilant currently targets only the highly regulated US and European markets with production from a USFDA approved facility in Maryland, USA and a newly-commissioned plant at Roorkee, India, which is also approved by USFDA and UK MHRA.

The Generic dosage form business is carried out by Cadista Pharmaceuticals in the United States and Jubilant Pharmaceuticals EU in the European Union. As part of the Jubilant Life Sciences family of companies, Cadista and Jubilant Pharmaceuticals EU capitalise on complete vertical integration from base chemicals to final distribution and

increasingly focus on relevant extended and immediate release oral solid products to deliver high value to the global market place.

The Generic dosage forms business has a strong portfolio of 70+ ANDAs and dossiers in various stages of development. Cadista currently markets 10 ANDAs, and both Cadista and Jubilant Pharmaceuticals EU expect to launch 10 to 12 products per year over the next 5 to 7 years.

As of March 31, 2010, we have filed 13 ANDAs in USA and 10 dossiers in Europe.

Key Offerings

- Immediate Release Products - Coated & Uncoated
 - Hard Gelatin Capsules
- Novel Drug Delivery Products
 - Controlled Release, Delayed Release & Sustained Release
 - Value Added Generics such as Mouth Dissolving, Chewable, Powder for Suspension etc.



Contract Manufacturing of Sterile and Non-Sterile Products

Jubilant's Contract Manufacturing (CMO) business is well positioned to service the spectrum of life sciences industry requirements from large scale leading pharmaceutical companies to virtual biotechnology organisations.

Jubilant operates in North America with two facilities that specialise in the manufacture of sterile and non-sterile products. Two independently branded CMOs in North America, HollisterStier Contract Manufacturing located in Spokane, Washington, USA and Draxis Pharma located in Montreal, Canada, offer sterile and non-sterile manufacturing services.

Both HollisterStier Contract Manufacturing and Draxis Pharma are recognised globally for their quality, execution, manufacturing capabilities and strong regulatory track records.

The cGMP facilities are qualified for the manufacture of clinical to commercial sized batches of small volume parenterals, along with

multiple other dosage forms. Providing various manufacturing capabilities has enhanced Jubilant's ability to provide "one-stop-shop" services to customers and has substantially increased the size and scope of its CMO business.

One of our core capabilities is our lyophilization services — our facilities offers over 1,800 sq.ft. of combined lyophilizer shelf space, automatic load/unload of vials, cold shelf loading capabilities down to -45°C, a dehumidification system designed by our expert engineers and nondestructive lighthouse analysis for monitoring container closure integrity. We offer these latest advances in parenteral technology to ensure that your sterile injectable moves safely and smoothly to the pharmacy shelf.

Key Offerings

Sterile Product Manufacturing Offerings:

- Manufacturing fill and finish of Phase 1 through to commercial parenteral dosage forms
- Clinical to Large-scale commercial Lyophilization
- Liquid vial and Ampoule formulations
- Ophthalmics
- Biologics and Proteins
- Parenteral devices
- Microspheres and Liposomes
- Laboratory development

Non-Sterile Product Manufacturing Offerings:

- Manufacturing fill and finish of commercial semi-solid and oral dosage forms
- Dermatological Ointments
- Antibiotic Ointments
- Syrups, Suspensions and Gels
- Capsules
- Tablets
- Powder blends



Drug Discovery and Development Solutions

The Drug Discovery and Development Solutions (DDDS) group is integrated across therapeutic areas of Oncology, Metabolic Diseases, Central Nervous System (CNS) and Infectious Diseases. It collaborates with global pharmaceutical companies, biotech and academia for lead generation, pre-clinical & clinical drug development across various target and technology disease platforms.


The Drug Discovery and Development Solutions (DDDS) group within Jubilant constitutes 3 of its subsidiaries, Jubilant Biosys, Jubilant Chemsys and Clinsys Clinical Research. With over 1000 highly skilled and experienced scientific and


medical personnel spread across Bengaluru and Noida in India, Europe and the US, the DDDS group leverages the capabilities in emerging markets for a global outcome, accelerating the global drug development efforts.

Our DDDS business offers integrated services platform across Target Validation, Discovery, Preclinical and Clinical Development

Drug discovery and development at Jubilant is driven by the passion to provide affordable drugs to the patients worldwide in the areas of unmet needs. Jubilant scientists collaborate across technology and therapeutic platforms to identify and validate novel small molecules

and platforms that will enable first or best in class healthcare efforts of our collaborators. High quality innovation is supported by a robust and highly efficient R&D process that makes Jubilant the preferred partner for many global pharmaceutical and biotech companies.





Jubilant's talent pool is a blend of PhDs, MDs and Masters, across various disciplines, and brings a wide range of experience from global pharmaceutical companies, biotech and academia.

The scientific team is well supported by a team of experienced and trained project managers for successful execution. ISO27001 compliant processes enable a secure IT infrastructure for real time, transparent and secure communications with all collaborators.

State-of-the-art infrastructure and enabling technologies further augment Jubilant's philosophy of creative partnering and provides all collaborators optimal outcome in managing their functional and portfolio needs.

The state-of-the-art technology platforms span across In Silico modeling, Protein Crystallography, High Throughput Screening and profiling technologies including in vivo screening technologies and parallel synthesis in the discovery area; and also extends to EDC platforms in Clinical development. Jubilant also partners with technology companies across the world in enabling cutting edge discovery and development efforts.

Jubilant Collaboration Strategy


Since its inception, Jubilant's business model of providing functional services and shared risk partnerships across discovery and pre-clinical/clinical development portfolio has received wide acceptance and is demonstrated by the continuing long term and sustainable partnerships that the DDDS group has been able to enter.

Creative partnering efforts include:

- Risk sharing models across Discovery, preclinical and early phase development
- Collaborative Functional Outsourcing Programs
- Strategic Sourcing alignment- Build to suit
- Performance based/milestone based payment terms
- Accelerated asset development models
- Joint Ventures- strategic drug discovery and development

Creating Value Through Collaboration

Discovery ► Development ► Product/Commercialisation



Jubilant's services and integrated collaborations are designed to align with all collaborators' therapeutic strategies across lead generation, pre-clinical and clinical development platforms. The Company provides functional and integrated solutions across the entire value chain of discovery and development to include:

Drug Discovery and Pre-clinical Development Solutions

- Integrated Target to Candidate ready solutions across target platforms of Kinases, GPCRs, Ion Channels, Proteases etc.
- Functional services augmenting capacity needs of the collaborators across:
 - Molecular Modeling: Structure Based Drug Design, Fragment based Discovery
 - Medicinal Chemistry and Scale-up Services: Design, SAR support, Library design, Scale-up, pre-formulation and characterisation support
 - Structural Biology: Gene to Structure Services
- High Throughput Screening and Profiling services across multiple target platforms
- ADME/PK, Toxicology in Rodents, Rabbits and Dogs
- In vivo efficacy models across Oncology, CNS, Pain / Inflammation and Metabolic Diseases
- Target validation and Biomarker services to include Tissue Banking
- Informatics Services – Pathway analysis, Customised biomarker and Target knowledge databases to enable discovery and clinical development efforts

Our Commitment

Within DDDS we strive to provide high quality innovation and a global platform for accelerated drug discovery and development solutions, enabling our collaborators to provide affordable and high quality healthcare to patients worldwide.

Clinical Development Solutions

Jubilant's therapeutically aligned clinical development capabilities provide collaborators a seamless transition from preclinical through translational and early stage development. This is further augmented by Jubilant's ability to provide global access to late stage development (Phase II-IV) across Europe, USA and India.

Clinsys clinical research, the clinical research group within DDDS, provides pharmaceutical, biotechnology and medical device companies with a broad range of clinical research services in support of Phase I-IV drug and device development, including project management, clinical monitoring, scientific and medical support, investigator and patient recruitment, site management, biostatistics, data management, EDC, drug safety, quality assurance, regulatory affairs, strategic sourcing and medical writing.

Highly efficient globally leveraged project management teams are supported by therapeutic experts in areas of Dermatology, Central Nervous System (CNS), Oncology, Respiratory and Cardiovascular Systems (CVS) providing collaborators with strategic and operational support from study design through regulatory approvals.

The Clinical Research group seamlessly integrates with customers or Jubilant's discovery and pre-clinical infrastructure to provide high quality and highly efficient translational and clinical development solutions to include:

- **Scientific foundation**
 - Therapeutic Program Strategists (Clinsys TPSTM)
 - Phase I unit (BA/BE, PK, generics and pre-formulation)
 - Trial design
 - Scientific advisory board for each therapeutic area
- **Sites/Patients access**
 - Global investigator network
 - Global feasibility
 - Expedited patient enrollment
 - Site training and validation
- **Technology**
 - Clinsys Trialstat CA, the first software as a service (SaaS)- based electronic data capture (EDC) system in the industry
 - Strategic alliances with vendors across multiple platforms and systems
- **Precision, execution and accountability**
 - Clinsys Global Project Solution (Clinsys GPS) Executive steering committee assigned to each project
 - Shared metrics/ transparent processes

The team of Jubilant's scientists, with global backgrounds, work seamlessly across technology and therapeutic areas to drive innovation and projects for the collaborations.



Healthcare – Hospitals



The Company's philosophy to provide "Better care at lower cost" is currently targeted towards the middle income population in the vast districts and towns of West Bengal, India.

The Healthcare business operates through Jubilent First Trust Healthcare (JFTH).

The Company aims to achieve its objective by continuing its focus on rationalisation of capital expenditure, process driven systems, evidence based practice of medicine through its dedicated team of doctors and innovative, low cost, business development policies.

Jubilant is developing an integrated, hub and spoke model of hospitals in West Bengal, involving 1 tertiary, super speciality 400 bed hospital (Hub) at Howrah; and 6 secondary, multi-speciality 100 bed hospitals (Spoke) in towns of South Bengal thus creating 1000 beds infrastructure. There will be two nursing schools as well.

The Company recently opened Jubilent Kalpataru Hospital – a 120-bed super-speciality hospital in Barasat, West Bengal.

The team of Full-time Doctors focuses on evidence-based medical practice, modern technology, efficient and contemporary hospital design – all combine with a transparent and caring environment; to deliver 'world-class

care at affordable cost'. The spread of the network of hospitals and the innovations in delivery such as NightLine service ensures access to medical care for a large population of West Bengal, districts and villages.

Leading Jubilent Kalpataru is a team of five senior doctors, trained in UK & USA, with over 15 years of experience, on their return from abroad. The hospital also has a multi-disciplinary team of Full-time doctors in all major specialties, who are resident in the hospital while on-call and available to lead emergency care to patients – a feature that immensely creates confidence among patients and improves the standard of care.

The hospital uses cutting-edge technology in providing safe and effective medical care, ethically and transparently. The entire effort is supported by a motivated team of nurses, other para-medical personnel and an efficient managerial team.

The Company is actively pursuing collaboration with various reputed national and international institutes for research proposals that can impact a large cross section of the population.



Research and Development

Jubilant's progress in diverse businesses has been made possible through the contribution of R&D for quality, non-infringing processes for product development and cost reduction through process innovation.

We are committed to leverage innovation at every stage of the pharma value chain to deliver value to our partners and enable them to take their products to the market faster and remain competitive overall.

Innovation in Jubilant is backed by strong chemistry and bio-science expertise and the knowledge bank created by the Company over the years. The Company has harnessed its strengths – a strong R&D team, modern R&D facilities, command over

the chemical technologies and economies of scale – into a synergistic organic entity, continuously creating and nurturing high quality products and technologies.

Key R&D activities

- Product development of Advance Intermediates, Fine Chemicals, Active Pharmaceutical Ingredients and Generic Dosage Forms
- Continuous process improvement for cost reduction to provide long-term sustainability to various businesses
- Collaborative drug discovery research which involves discovery informatics, functional chemistry and crystallography
- Contract research on projects and FTE basis to support our customers' pre-clinical and clinical development programmes
- Clinical research and BA/BE/PK studies



Accelerating for Growth

Facilities

- Parallel synthesis lab
- Gram scale synthesis lab
- Analytical lab
- Process research lab
- Kilo lab
- Pilot plant and semi-commercial plant
- USFDA approved manufacturing location with steroid capabilities

Analytical Support Equipment

- NMR (400 MHz)
- HPLC (Analytical & Prep)
- GCs (with head space), GPCs
- GCMS, LC-MS/MS
- UV-VIS Spectrometer
- Polarimeter
- FTIR
- XRD (3KVA with accelerator detector)
- AAS



Business Excellence

Jubilant's ambition of achieving leadership in various businesses is fuelled by the Company's strategy of continuous improvement enabled through business excellence.

Jubilant's Business Excellence Model is created around three Pillars of Customer, Process and People. This is achieved by focused process improvement efforts in functions like Supply Chain, Manufacturing, Sales and Marketing.

Customer Excellence

Project Management Infrastructure created through Microsoft Server based Enterprise wide Project Management Tool.

All Project Managers and Engineers are trained in PMI, globally recognised Project Management Institute's methodology. This tool helps to manage the time and cost performance for various Capital and Customer product Development Projects undertaken.

Customer Dashboards and Forecasting:

The Business excellence function has developed expertise in an array of Business Intelligence tools like Igrafx, Qlik View, Excelius and Forecast Pro which are used in numerous projects, creating analytical reports from ERP to enable better business decisions and statistical Forecasting of Volumes and Revenue.

Process Excellence

Supply Chain Excellence through SCOR:

Process reference models are used to integrate the well-known concepts of business process re-engineering, benchmarking, and process measurement into a cross-functional framework. This has helped in creating a very cost efficient & agile Supply Chain.

Manufacturing Excellence through Lean Six Sigma:

Lean at Jubilant is focused on increasing value for the customer by removing wastes from the processes so that the value can seamlessly get transformed in the processes at the pull of the customer. Very effectively used to cut down the cycle time / reducing cost and improving responsiveness to the customers.

Design Excellence through DFSS (Design for Six Sigma):

This methodology helps cut the Product Development / Process Development cycle time by a stage gate process approach and using the tools to optimise and right first time at each of the stages, thus avoiding reworking the development. Investing larger time in planning than execution ensures that the Company has the right "Time to Market" for the product. Design of experiments help cut down the effort and cost needed to arrive at the optimal solution.

Six Sigma is a way of life at Jubilant, to address any process variation that increases cost and also impacts the customer's requirements. Through Six Sigma approach, the Company strives to continuously work on Process optimisation, Variability reduction and Quality improvement to give the customers "What they need and when they need".

TPM at Jubilant has resulted in great motivation of grass root level employees to improve effectiveness and utilisation of assets and implement improvements which have extended the life & utilisation of the equipments and plants.



People Excellence

Performance Management System through Balanced Scorecard and Hoshin Kanri:

Performance Management system is a key driver in performance of any Organisation. The Company uses the Balanced Scorecard mechanism till the middle management level to ensure that the goals of the people are drawn and aligned with the Strategic Objectives of the Organisation.


To prevent duplication of roles and responsibilities, the Hoshin way is used to deploy these goals in a top down manner. The 'What's or Goals' of the Superior are drilled down in terms of How's and these How's become the 'What's/Goals' of the next level.

Employee Engagement through Gallup's Q12 Philosophy:

Gallup has a very well researched philosophy of 12 questions around which Employee's expectations in all Organisations can be measured. Jubilant has administered this assessment across all businesses globally to understand the employees' expectations and listen to their suggestions to make the Organisation 'A Great Place to Work'.

There has been drastic improvement in the Employee engagement scores seen over the past two cycles and highly improved retention rate and productivity improvement through this initiative. The Company is committed to listen to the views of employees and ensure actions to address their expectations through the Q12 methodology.

Employing Lean Six Sigma, Kaizen, TPM (Total Productivity Management), WCM (World Class Manufacturing) and SCOR (Supply Chain Operations Reference) and Project Management has helped Jubilant grow to new levels of competency and efficiency.



Corporate Sustainability

Jubilant's rapid growth has been facilitated by a robust sustainability strategy that aims at going beyond legislative requirements to develop a sustainable business model.

Jubilant focuses on the triple bottom line approach of addressing economic, environmental and social performance while doing business. It also stresses on Corporate Governance which is the guiding pillar for the triple bottom line approach and follows a structured methodology for risk identification and management.

Economic

- Continue to enhance value by achieving average return on invested capital 10 points higher than the weighted average cost of capital
- Provide innovative products and cost effective solutions to customers
- Contribute to National exchequer in the form of taxes
- Regular and timely payment to business partners
- Maintain transparency in sharing information with stakeholders
- Improve employee well being through increased benefits

Environment

- Maximise use of renewable raw materials and energy efficient processes
- Conserve and reduce energy and other resources used including water
- Reduce and recycle wastes
- Integrate environment aspects at project conceptualisation stage
- Actively participate in mitigating global environmental concerns

Jubilant's Corporate Sustainability Program has been recognised by institutions like Global Reporting Initiative (GRI), International Finance Corporation (IFC) and Confederation of Indian Industry (CII).






Social

- Contribute towards improving the quality of life of the neighbouring community around its manufacturing locations since Jubilant considers them an important group of stakeholders.
- Identify areas of social intervention through need assessment studies
- Provide basic healthcare including diagnosis and treatment of Tuberculosis (TB) and counseling and testing of HIV/AIDS through an Integrated Counseling and Testing Centre (ICTC), supporting rural Government primary education system and running livelihood generation programme. These are the focus areas of the Company's social interventions, based on the need assessment studies
- Help push the well conceived Government schemes in chosen areas through Public, Private, People, Partnership (4P) approach
- Increase involvement of employees in social activities


Corporate Governance & Risk Management

- Maintain high level of transparency in Governance
- Comply with revised Clause 49 of the Securities and Exchange Board of India (SEBI) on accuracy of financial statements and adequacy of internal controls and risk management
- Identify and implement a strong risk management framework that enables active monitoring of business activities for assessment and mitigation of potential internal and external risks
- Communicate regularly with the stakeholders



Jubilant is committed to continue its efforts to address the sustainability issues in future while striving to improve its performance on the triple bottom line.

Jubilant Across the Globe



- **International sales** in more than **65 countries**
- Present in **India, North America, Europe** and **China**
- **8 manufacturing facilities** in **India** and **3** in **North America**
- **Drug Discovery Centre** in **India** and **Multiple R&D Centres** in **India & Overseas**
- **Employs ~ 6000** people including **~1100** in **R&D** and **~1500** in **North America**

Manufacturing Locations

Jubilant Life Sciences has eleven geographically diversified manufacturing facilities in India and North America. These facilities are GMP and GLP compliant and have ISO 9001:2000, ISO 14001 & ISO 18001 accreditations. The plants are also approved by the relevant international regulatory authorities.

Over the last few years Jubilant has successfully integrated R&D, technology and engineering capabilities and with implementation of Lean Six Sigma for continuous improvement and cost management, the Company offers its customers the best in class products and services.



1



2



3



4



5



6



7



8



9



10

Manufacturing Facilities - India (Existing)

1. Gajraula, UP (Proprietary Products) 2. Nanjangud, Karnataka (APIs) 3. Roorkee, UP (Generic Dosage Forms) 4. Kapasan, Rajasthan (Single Super Phosphate) 5. Speciality Molecules Ltd. Ambernath, Maharashtra (Proprietary Products - Fine Chemicals) 6. Nira, Maharashtra (Industrial Products and Performance Polymers) 7. Samlaya, Gujarat (Performance Polymers)

Manufacturing Facilities - North America

8. Cadista Pharmaceuticals Inc., Maryland, USA (Generic Dosage Form) 9. HollisterStier Laboratories, Spokane, USA (CMO Sterile & Non-Sterile and Allergenic Extracts) 10. Draxis Speciality Pharmaceuticals Inc., Kirkland, Canada (CMO Sterile & Non-Sterile and Radiopharma)

Manufacturing Facilities - India (Upcoming)

11. Facility at SEZ in Gujarat for Nutrition Products



Awards & Recognition

- Golden Peacock Environment Management Award 2010 by World Environment Foundation (WEF) for API facility at Nanjangud, Mysore, India
- NDTV Profit Business Leader of the Year 2009 as the Best Pharmaceutical Company
- PHD Chamber Annual Excellence Award 2009 for Good Corporate Citizen
- Acharya PC Ray Award 2009 for Development of Indigenous Technology for 4DMAP
- Industry Excellence Award 2009 from Institution of Engineers India, Kolkata
- Frost and Sullivan – India Excellence in Healthcare Award as the Best Contract Research Manufacturing Organisation of the Year 2009
- ET – IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud
- Corporate Excellence Award 2009 as the Best Pharma Company from the Amity University
- Business Excellence Award 2009 to our Samlaya plant by Baroda Management Association
- Bio-Services Company of the Year 2009 for Jubilant Biosys awarded by BioSpectrum Magazine
- BioSpectrum Person of the Year 2009 Award conferred upon Hari S Bhartia, Co-Chairman & Managing Director of the Company
- Best Performing CFO 2009 of the year for the Pharma Sector to R Sankaraiah by CNBC-TV18
- Best CFO for the year 2009 (FMCG, Health and Retail Sector) to R Sankaraiah by Institute of Chartered Accountants of India

Jubilant Life Sciences Ltd.

Principal International Subsidiaries

USA

Cadista Pharmaceuticals Inc.

207, Kiley Drive, Salisbury, Maryland 21801, USA

T: +1 410 860 8500

F: +1 410 860 8719

Clinsys Clinical Research, Inc.

1 Crossroads Drive, Building A, Second Floor, Bedminster, NJ 07921, USA

T: +1 908 658 9988

F: +1 908 658 9927

Hollister-Stier Laboratories, LLC.

3525, N. Regal, Spokane, Washington 99207, USA

T: +1 509 489 5656

F: +1 509 484 4320

Jubilant Organosys (USA) Inc.

1 Crossroads Drive, Building A, Second Floor, Bedminster, NJ 07921, USA

T: +1 908 658 9988

F: +1 908 658 9927

Canada

DRAXIS Specialty Pharmaceuticals, Inc.

16751, TransCanada Highway, Kirkland (Montreal), Québec, Canada H9H 4J4

T: +514 630 7030

F: +514 694 9295

Belgium

Jubilant Pharmaceuticals N.V.

AXXES BUSINESS PARK, Guldensporenpark, Blok C - nr. 22, Gelijkvloers Links, 9820 Merelbeke, Belgium

T: +32 9 233 1404

F: +32 9 233 0016

PSI Supply N.V.

AXXES BUSINESS PARK, Guldensporenpark, Blok C - nr. 22, Gelijkvloers Links, 9820 Merelbeke, Belgium

T: +32 9 233 1404

F: +32 9 233 0016

China

Jubilant Organosys (Shanghai) Ltd.

Room No. 3403, Hongkong Plaza, South Tower, 283, Huai Hai Zhong Road, Shanghai-200021, China

T: +86 21 6390 7388

F: +86 21 6390 7399

Principal Indian Subsidiaries

NOIDA

Clinsys Clinical Research Ltd.

C-46, Sector 62, Noida-201307, Uttar Pradesh, India

T: +91 120 436 4000

F: +91 120 240 4336

Jubilant Chemsys Ltd.

D-12, Sector 59, Noida-201301, Uttar Pradesh, India

T: +91 120 409 3300

F: +91 120 258 6776

Jubilant Infrastructure Ltd.

1A, Sector 16A, Noida-201 301, Uttar Pradesh, India

T: +91 120 251 6601-11

F: +91 120 251 6628-30

Bengaluru

Jubilant Biosys Ltd.

No.96, Industrial Suburb, 2nd Stage Industrial Area, Yeshwantpur, Bengaluru-560022, India

T: +91 80 6662 8400

F: +91 80 6662 8333

Kolkata

Jubilant First Trust Healthcare Ltd.

78, Jessore Road, South Barasat, Kolkata 700127
24 pgs (North) West Bengal, India

T: +91 33 4036 3636

F: +91 33 2584 2855



Corporate Office

1A, Sector 16A, Noida-201301, Uttar Pradesh, India

Tel: +91 120 2516601-11 Fax: +91 120 2516628-30

email: support@jubl.com

www.jubl.com